GF CSI Innovative Drugs Industry ETF (515120) Rises 3.23%, Sees Share Growth of 114 Million Units Over the Past Week

NewTimeSpace News, as of 09:45 on April 28, 2026, GF Innovative Drug ETF (515120) rose 3.23%, with its latest quoted price at 0.64 yuan. Looking at a longer timeframe, as of April 27, 2026, GF Innovative Drug ETF gained 1.64% over the past month. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 2.36%, with a trading volume of 233 million yuan. Over a longer horizon, as of April 27, the ETF's average daily turnover over the past month stood at 433 million yuan, ranking in the top 2 among comparable funds.

Regarding scale, GF Innovative Drug ETF's AUM increased by 6.4242 million yuan over the past week, achieving significant growth, with the new scale increment ranking 2/7 among comparable funds. (Data source: Wind)

In terms of share size, GF Innovative Drug ETF's share count increased by 114 million units over the past week, achieving significant growth, with the new share increment ranking 1/7 among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net inflow for GF Innovative Drug ETF was 9.8716 million yuan. Looking at a longer timeframe, over the past five trading days, there were four days of net inflows, totaling 187 million yuan, with an average daily net inflow of 37.4998 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for GF Innovative Drug ETF month-to-date reached 1.3218 million yuan, and the latest margin balance stood at 332 million yuan. (Data source: Wind)

As of April 27, GF Innovative Drug ETF's net value increased by 20.42% over the past two years. In terms of return capability, as of April 27, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest consecutive gaining streak of five months with a cumulative gain of 32.68%, and an average return of 5.63% during up months. As of April 27, 2026, the ETF's annualized excess return over its benchmark over the past two years was 0.86%.

In terms of drawdown, as of April 27, 2026, GF Innovative Drug ETF's relative drawdown versus its benchmark since the beginning of the year was 0.14%, indicating relatively low drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking accuracy, as of April 27, 2026, GF Innovative Drug ETF's tracking error since the beginning of the year was 0.009%, the highest tracking precision among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index, which GF Innovative Drug ETF tracks, is only 40.99 times, placing it at the 0.38th percentile over the past year—meaning the valuation is lower than that of over 99.62% of the time in the past year, indicating a historically low level.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main business involves innovative drug research and development as index constituents, in order to reflect the overall performance of listed company securities in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.